Abstract |
Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician's office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.
|
Authors | J B Raffel, O Malik, R S Nicholas |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 20
Issue 1
Pg. 24-6
(Jan 2014)
ISSN: 1477-0970 [Electronic] England |
PMID | 23727943
(Publication Type: Journal Article)
|
Chemical References |
- Potassium Channel Blockers
- 4-Aminopyridine
|
Topics |
- 4-Aminopyridine
(therapeutic use)
- Humans
- Mobility Limitation
- Multiple Sclerosis
(complications, drug therapy)
- Physicians' Offices
- Potassium Channel Blockers
(therapeutic use)
- Treatment Outcome
- Walking
|